Impact of comorbidities and use of common medications on cancer and non-cancer specific survival in esophageal carcinoma

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  He, Li Ru ^b   Qiao, Wei ^a   Liao, Zhong Xing ^a   Komaki, Ritsuko ^a   Ho, Linus ^a   Hofstetter, Wayne L ^a   Lin, Steven H ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Comorbidity; Esophageal carcinoma; Medication; Survival

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTACID AGENT; ANTICOAGULANT AGENT; ANTIDEPRESSANT AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE; BRONCHODILATING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIAC GLYCOSIDE; CORONARY VASODILATING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INSULIN; LEVOTHYROXINE; NONSTEROID ANTIINFLAMMATORY AGENT; SULFONYLUREA DERIVATIVE; ANTIHYPERTENSIVE AGENT; METFORMIN; THYROXINE;

ADULT; AGED; ARTICLE; ATRIAL FIBRILLATION; CANCER MORTALITY; CANCER SPECIFIC SURVIVAL; COMORBIDITY; DRUG USE; ESOPHAGUS CARCINOMA; FEMALE; HUMAN; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL RATE; ASTHMA; CHEMORADIOTHERAPY; DIABETES MELLITUS; ESOPHAGEAL NEOPLASMS; ESOPHAGUS RESECTION; HYPERTENSION; MIDDLE AGED; MORTALITY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIHYPERTENSIVE AGENTS; ASTHMA; ATRIAL FIBRILLATION; CHEMORADIOTHERAPY; COMORBIDITY; DIABETES MELLITUS; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; HUMANS; HYPERTENSION; HYPOTHYROIDISM; MALE; METFORMIN; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; SURVIVAL RATE; THYROXINE; YOUNG ADULT;

EID: 84928710706     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1095-2     Document Type: Article

References (25)

1. Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel Jr EL. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004;291:2441-7.
2. Koppert LB, Lemmens VE, Coebergh JW, Steyerberg EW, Wijnhoven BP, Tilanus HW, et al. Impact of age and co-morbidity on surgical resection rate and survival in patients with oesophageal and gastric cancer. Br J Surg. 2012;99:1693-700.
3. Backemar L, Djarv T, Wikman A, Johar A, Ross P, Lagergren P, et al. The role of diabetes and other co-morbidities on survival after esophageal cancer surgery in a population-based study. Am J Surg. 2013;206:539-43.
4. Skinner HD, McCurdy MR, Echeverria AE, Lin SH, Welsh JW, O'Reilly MS, et al. Metformin use and improved response to therapy in esophageal adenocarcinoma. Acta Oncol. 2013;52:1002-9.
5. Nguyen T, Khalaf N, Ramsey D, El-Serag HB. Statin Use is Associated with a Decreased Risk of Barrett's Esophagus. Gastroenterology. 2014;147(2):314-23.
6. Sadeghi S, Bain CJ, Pandeya N, Webb PM, Green AC, Whiteman DC, et al. Aspirin, nonsteroidal anti-inflammatory drugs, and the risks of cancers of the esophagus. Cancer Epidemiol Biomarkers Prev. 2008;17:1169-78.
7. WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects. [http://www.wma.net/en/30publications/10policies/b3/index.html]
8. Pal SK, Hurria A. Impact of age, sex, and comorbidity on cancer therapy and disease progression. J Clin Oncol. 2010;28:4086-93.
9. Bhave PD, Goldman LE, VittinghoffE, Maselli J, Auerbach A. Incidence, predictors, and outcomes associated with postoperative atrial fibrillation after major noncardiac surgery. Am Heart J. 2012;164:918-24.
10. Ma JY, Wang Y, Zhao YF, Wu Z, Liu LX, Kou YL, et al. Atrial fibrillation after surgery for esophageal carcinoma: clinical and prognostic significance. World J Gastroenterol. 2006;12:449-52.
11. Martinez-Iglesias O, Garcia-Silva S, Regadera J, Aranda A. Hypothyroidism enhances tumor invasiveness and metastasis development. PLoS One. 2009;4:e6428.
12. Hercbergs AH, Ashur-Fabian O, Garfield D. Thyroid hormones and cancer: clinical studies of hypothyroidism in oncology. Curr Opin Endocrinol Diabetes Obes. 2010;17:432-6.
13. Nelson M, Hercbergs A, Rybicki L, Strome M. Association between development of hypothyroidism and improved survival in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2006;132:1041-6.
14. Riesenbeck LM, Bierer S, Hoffmeister I, Kopke T, Papavassilis P, Hertle L, et al. Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib. World J Urol. 2011;29:807-13.
15. Cristofanilli M, Yamamura Y, Kau SW, Bevers T, Strom S, Patangan M, et al. Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma. Cancer. 2005;103:1122-8.
16. Garfield D. Hypothyroidism promotes survival. Lancet Oncol. 2002;3:328.
17. Moeller LC, Fuhrer D. Thyroid hormone, thyroid hormone receptors, and cancer: a clinical perspective. Endocr Relat Cancer. 2013;20:R19-29.
18. Brown AR, Simmen RC, Simmen FA. The role of thyroid hormone signaling in the prevention of digestivesystem cancers. Int J Mol Sci. 2013;14:16240-57.
19. Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH, Huang YC. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer. 2011;11:20.
20. Feng Y, Ke C, Tang Q, Dong H, Zheng X, Lin W, et al. Metformin promotes autophagy and apoptosis in esophageal squamous cell carcinoma by downregulating Stat3 signaling. Cell Death Dis. 2014;5:e1088.
21. Sadaria MR, Reppert AE, Yu JA, Meng X, Fullerton DA, Reece TB, et al. Statin therapy attenuates growth and malignant potential of human esophageal adenocarcinoma cells. J Thorac Cardiovasc Surg. 2011;142:1152-60.
22. Galipeau PC, Li X, Blount PL, Maley CC, Sanchez CA, Odze RD, et al. NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med. 2007;4:e67.
23. Choe KS, Cowan JE, Chan JM, Carroll PR, D'Amico AV, Liauw SL. Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. J Clin Oncol. 2012;30:3540-4.
24. Yu O, Eberg M, Benayoun S, Aprikian A, Batist G, Suissa S, et al. Use of statins and the risk of death in patients with prostate cancer. J Clin Oncol. 2014;32:5-11.
25. Zhang ZJ, Li S. The prognostic value of metformin for cancer patients with concurrent diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2014;16(8):707-10.